Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Profit After Tax of -$19.8 million for Q1 2026, down 34.42% year-over-year from -$30.2 million in Q1 2025, and little changed quarter-over-quarter from -$19.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at -$19.8 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 34.42% year-over-year to -$19.8 million; the TTM figure through Mar 2026 stood at -$69.5 million (up 46.45% YoY), while the FY2025 annual figure was -$64.9 million, up 50.84% from the prior year.
- Profit After Tax for Q1 2026 stood at -$19.8 million, roughly flat from -$19.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$700000.0 in Q4 2023, with the low at -$96.6 million in Q4 2024.
- The 5-year median for Profit After Tax is -$19.8 million (2025), against an average of -$22.9 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 97.35% in 2023, then tumbled 13693.14% in 2024.
- Aclaris Therapeutics' Profit After Tax stood at -$26.4 million in 2022, then jumped by 97.35% to -$700000.0 in 2023, then sank by 13693.14% to -$96.6 million in 2024, then jumped by 79.5% to -$19.8 million in 2025, then retreated by 0.15% to -$19.8 million in 2026.
- Business Quant data shows ACRS's Profit After Tax at -$19.8 million in Q1 2026, -$19.8 million in Q4 2025, and -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.83 Mn |
| Mar 31, 2026 | -19.82 Mn |
| Dec 31, 2025 | -19.80 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Jun 30, 2025 | -15.43 Mn |
| Mar 31, 2025 | -14.75 Mn |
| Dec 31, 2024 | -96.55 Mn |
| Sep 30, 2024 | -7.59 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -16.94 Mn |
| Dec 31, 2023 | -700,000.00 |
| Sep 30, 2023 | -29.28 Mn |
| Jun 30, 2023 | -29.57 Mn |
| Mar 31, 2023 | -28.16 Mn |
| Dec 31, 2022 | -26.39 Mn |
| Sep 30, 2022 | -19.95 Mn |
| Jun 30, 2022 | -20.53 Mn |
| Mar 31, 2022 | -18.79 Mn |
| Dec 31, 2021 | -22.93 Mn |
| Sep 30, 2021 | -20.97 Mn |